ProtoKinetix, Inc. (PKTX) Financial Statements (2024 and earlier)

Company Profile

Business Address 109 W. MAIN ST.
DALTON, OH 44618
State of Incorp. NV
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments18,6556,94225,55043,71218,83058,879
Cash and cash equivalents18,6556,94225,55043,71218,83058,879
Prepaid expense1,0501,0501,0501,0501,0501,050
Total current assets:19,7057,99226,60044,76219,88059,929
Noncurrent Assets
Intangible assets, net (including goodwill)447,275439,310436,270434,977393,162367,498
Intangible assets, net (excluding goodwill)447,275439,310436,270434,977393,162367,498
Total noncurrent assets:447,275439,310436,270434,977393,162367,498
TOTAL ASSETS:466,980447,302462,870479,739413,042427,427
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities13,25553,00041,530105,03336,7807,000
Accounts payable13,25553,00041,530105,03336,7807,000
Total current liabilities:13,25553,00041,530105,03336,7807,000
Noncurrent Liabilities
Total liabilities:13,25553,00041,530105,03336,7807,000
Equity
Equity, attributable to parent453,725394,302421,340374,706376,262420,427
Common stock1,7951,7471,7261,6811,6411,625
Additional paid in capital48,123,02447,948,07247,868,09347,237,84746,869,40146,477,564
Accumulated deficit(47,671,094)(47,555,517)(47,448,479)(46,864,822)(46,494,780)(46,058,762)
Total equity:453,725394,302421,340374,706376,262420,427
TOTAL LIABILITIES AND EQUITY:466,980447,302462,870479,739413,042427,427

Income Statement (P&L) (USD)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Operating expenses(115,577)(107,038)(583,657)(370,042)(442,153)(517,592)
Operating loss:(115,577)(107,038)(583,657)(370,042)(442,153)(517,592)
Loss from continuing operations:(115,577)(107,038)(583,657)(370,042)(442,153)(517,592)
Loss before gain (loss) on sale of properties:(370,042)(442,153)(517,592)
Other undisclosed net loss      
Net loss:(115,577)(107,038)(583,657)(370,042)(442,153)(517,592)
Other undisclosed net income attributable to parent    884,306 
Net income (loss) available to common stockholders, diluted:(115,577)(107,038)(583,657)(370,042)442,153(517,592)

Comprehensive Income (USD)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net loss:(115,577)(107,038)(583,657)(370,042)(442,153)(517,592)
Comprehensive loss, net of tax, attributable to parent:(115,577)(107,038)(583,657)(370,042)(442,153)(517,592)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: